melanoma, targeted therapy, BRAF and MEK inhibitors, Anticoagulation, Direct oral anticoagulants (DOACs), Factor Xa inhibitors, Progression-free survival (PFS), Overall survival (OS), Platelet aggregation inhibition, Venous thromboembolism (VTE), Immunothrombosis
melanoma, immune-checkpoint inhibitors, neutrophils, S100A8/A9, Biomarker
Melanoma, sex, Targeted therapy, immune checkpoint inhibition therapy, Survival
Programmed cell death ligand 1, cemiplimab, D-dimer, cutaneous squamous cell carcinoma, disease control